This article is more than 5 years old. Information may no longer be current.

QLT to study potential treatment for Leber’s congenital amaurosis, RP

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

QLT Inc. announced that it will soon finalize a protocol for a clinical trial of QLT091001 for treating inherited retinal disease such as Leber’s congenital amaurosis and retinitis pigmentosa, according to a company press release.

The company said in the release that it has also begun recruiting subjects for a phase 2a proof-of-concept trial of this agent in adults with impaired dark adaptation.

In addition, QLT has launched a compassionate use program of QLT091001 in Leber’s congenital amaurosis and RP.

"We are excited with the progress QLT has made with the program this past year and look forward to a productive next few months as we prepare this important therapy for a pivotal trial,” QLT Chairman of the Board Jason M. Aryeh said in the release.